Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 19, 2022, Eliem Therapeutics, Inc. (the "Company") held its 2022 Annual Meeting of Stockholders virtually via live webcast at www.proxydocs.com/ELYM (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on two proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2022. The following is a brief description of each matter voted upon and the certified voting results. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest round number.

Proposal No. 1. Stockholders elected each of the three nominees for Class I director to serve until the Company's 2025 Annual Meeting of Stockholders and until his or her respective successor has been duly elected and qualified. The final voting results were as follows:



                                                Broker

Director Name Votes For Votes Withheld Non-Votes Robert Azelby 20,565,991 2,231,598 1,346,296 Judith Dunn 20,570,020 2,227,569 1,346,296 Adam Rosenberg 20,383,841 2,413,748 1,346,296

Proposal No. 2. Stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The final voting results were as follows:



                                            Broker
Votes For    Votes Against   Abstentions   Non-Votes
24,137,141       4,086          2,658         -

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses